Twist Bioscience (NASDAQ:TWST) PT Lowered to $40.00 at Barclays

Twist Bioscience (NASDAQ:TWST) had its target price decreased by Barclays from $45.00 to $40.00 in a research note issued to investors on Wednesday morning, Benzinga reports. Barclays currently has an overweight rating on the stock.

TWST has been the topic of several other reports. Scotiabank lifted their price target on shares of Twist Bioscience from $30.00 to $43.00 and gave the company a sector outperform rating in a report on Monday, February 5th. The Goldman Sachs Group raised shares of Twist Bioscience from a neutral rating to a buy rating and lifted their price target for the company from $25.00 to $45.00 in a report on Wednesday, January 17th.

Twist Bioscience Trading Down 5.5 %

Shares of Twist Bioscience stock opened at $31.86 on Wednesday. The firm has a market capitalization of $1.84 billion, a PE ratio of -8.83 and a beta of 1.62. The firm’s 50 day moving average is $36.42 and its 200 day moving average is $29.60. Twist Bioscience has a 1 year low of $11.46 and a 1 year high of $43.21.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Friday, February 2nd. The company reported ($0.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.03. The company had revenue of $71.50 million for the quarter, compared to analyst estimates of $67.59 million. Twist Bioscience had a negative net margin of 78.44% and a negative return on equity of 32.16%. The firm’s revenue was up 31.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.74) EPS. As a group, research analysts anticipate that Twist Bioscience will post -3.17 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Emily M. Leproust sold 1,132 shares of the stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $32.74, for a total transaction of $37,061.68. Following the transaction, the chief executive officer now directly owns 514,149 shares of the company’s stock, valued at $16,833,238.26. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, Director Robert Chess sold 4,110 shares of the firm’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $34.98, for a total transaction of $143,767.80. Following the transaction, the director now directly owns 64,169 shares of the company’s stock, valued at $2,244,631.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Emily M. Leproust sold 1,132 shares of the firm’s stock in a transaction dated Tuesday, April 2nd. The shares were sold at an average price of $32.74, for a total transaction of $37,061.68. Following the transaction, the chief executive officer now directly owns 514,149 shares in the company, valued at $16,833,238.26. The disclosure for this sale can be found here. Insiders have sold a total of 10,481 shares of company stock valued at $365,655 over the last ninety days. 3.92% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. ARK Investment Management LLC lifted its position in shares of Twist Bioscience by 6.3% during the fourth quarter. ARK Investment Management LLC now owns 7,213,257 shares of the company’s stock valued at $265,881,000 after purchasing an additional 427,274 shares in the last quarter. BlackRock Inc. increased its holdings in Twist Bioscience by 11.1% during the second quarter. BlackRock Inc. now owns 6,905,031 shares of the company’s stock worth $141,277,000 after buying an additional 691,590 shares during the last quarter. State Street Corp increased its holdings in Twist Bioscience by 19.2% during the first quarter. State Street Corp now owns 5,275,841 shares of the company’s stock worth $79,560,000 after buying an additional 849,592 shares during the last quarter. Capital World Investors increased its holdings in Twist Bioscience by 6.0% during the first quarter. Capital World Investors now owns 4,795,848 shares of the company’s stock worth $236,819,000 after buying an additional 273,148 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in Twist Bioscience by 10.8% during the first quarter. Vanguard Group Inc. now owns 4,791,074 shares of the company’s stock worth $236,584,000 after buying an additional 467,466 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.